Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glofitamab + GemOx vs standard salvage therapy in relapsed/refractory large B-cell lymphoma
ChiCTR2600127367Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Jun 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of glofitamab in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by First Affiliated Hospital of Soochow University. Primary endpoint: Event-Free Survival. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
glofitamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ChiCTR2600127367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600127367.